Journal article · 2022
Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy
Cancer Research, 82(12_Supplement), 5559 · Published 15 June 2022 · DOI 10.1158/1538-7445.am2022-5559
In brief
“Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy” is a 2022 journal article by Haishan luo and 11 co-authors, published in Cancer Research. OpenAlex counts 2 citations as of 18 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 2
- Most cited in
- 2024 (2)
- Authors
- 12
Abstract
CD40 agonistic antibody is emerging as a front-line immunotherapy for patients with cancer. However, despite its remarkable curative effects, serious immune-related adverse reactions limit the clinical application of CD40 agonists. Crosslinking-dependent activation is one of the promising approaches to diminish the adverse effects of CD40 agonists. Agonistic CD40 stimulation on antigen presenting cells (APCs) not… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
luo, H., Meng, Z., Rong, J., Wang, Y., Yang, Y., Chen, F., Wang, Y., Chen, V., Deng, G., He, Y., Gan, X., & Rong, Y. (2022). Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy. Cancer Research, 82(12_Supplement), 5559. https://doi.org/10.1158/1538-7445.am2022-5559
MLA 9
luo, Haishan, et al. “Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy.” Cancer Research, vol. 82, no. 12_Supplement, 2022, p. 5559. https://doi.org/10.1158/1538-7445.am2022-5559.
Chicago
luo, Haishan, Zihong Meng, Jimmy Rong, Yuandong Wang, Yunxing Yang, Fei Chen, Youhong Wang, et al. 2022. “Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy.” Cancer Research 82 (12_Supplement): 5559. https://doi.org/10.1158/1538-7445.am2022-5559.
Harvard
luo, H. et al. (2022) ‘Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy’, Cancer Research, 82(12_Supplement), p. 5559. doi:10.1158/1538-7445.am2022-5559.
IEEE
H. luo et al., “Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy,” Cancer Research, vol. 82, no. 12_Supplement, p. 5559, 2022, doi: 10.1158/1538-7445.am2022-5559.
BibTeX
@article{luo2022abstract,
title = {{Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy}},
author = {luo, Haishan and Meng, Zihong and Rong, Jimmy and Wang, Yuandong and Yang, Yunxing and Chen, Fei and Wang, Youhong and Chen, Victor and Deng, Gang and He, Yebo and Gan, Xin and Rong, Yiping},
journal = {Cancer Research},
year = {2022},
volume = {82},
number = {12_Supplement},
pages = {5559},
doi = {10.1158/1538-7445.am2022-5559},
url = {https://doi.org/10.1158/1538-7445.am2022-5559}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- PD-1/PD-L1 blockade
- cancer immunotherapy
- immune-related adverse events
- antigen-presenting cells
- T cell activation
- antitumor efficacy
- preclinical toxicity
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
luo, H., Meng, Z., Rong, J., Wang, Y., Yang, Y., Chen, F., Wang, Y., Chen, V., Deng, G., He, Y., Gan, X., & Rong, Y. (2022). Abstract 5559: Development of a novel PD-L1xCD40 bispecific antibody with excellent efficacy and safety profile for cancer therapy. Cancer Research, 82(12_Supplement), 5559. https://doi.org/10.1158/1538-7445.am2022-5559
How many times has this paper been cited?
2 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Haishan luo, Zihong Meng, Jimmy Rong, Yuandong Wang, Yunxing Yang, Fei Chen, Youhong Wang, Victor Chen, Gang Deng, Yebo He, Xin Gan, Yiping Rong.
What is the DOI of this paper?
10.1158/1538-7445.am2022-5559, permanently at https://doi.org/10.1158/1538-7445.am2022-5559. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.